Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Square Power Ltd. operates a patent portfolio within the Biotechnology & Pharmaceuticals technology area. There are currently 3 pending office actions associated with this company, representing a moderate level of ongoing prosecution. This activity level indicates that the company is actively engaged in securing intellectual property rights for several different innovations or stages of development within the biotechnology sector.
The portfolio examination is spread across 3 distinct examiners but is contained within 2 distinct art units. This overlap in art units suggests that while different individuals are reviewing the applications, the technical subject matter remains relatively consistent across the filings. The use of 3 examiners for 3 pending actions means each active matter is being handled by a different person, which can lead to varied prosecution timelines and outcomes.
KETCHAM, KAREN A is the busiest examiner for the portfolio, with 1 busiest examiner pending action. Given that the total pending office actions count is 3, the workload is evenly distributed among the assigned staff. This lack of concentration with a single examiner suggests that the company success in this technology area depends on navigating the perspectives of multiple patent office officials rather than a single individual.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| THOMAS, TIMOTHY P | 1 | 26.3% | +38.0% |
| KETCHAM, KAREN A | 1 | 20.0% | +38.8% |
| LADD, CAROLYN LOUISE | 1 | 58.6% | +47.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17638871 | REBAMIPIDE FOR USE IN PREVENTION AND TREATMENT OF CROHN'S DISEASE | KETCHAM, KAREN A | 50d overdue |
| 17638868 | REBAMIPIDE FOR USE IN PROPHYLAXIS AND TREATMENT OF CELIAC DISEASE | THOMAS, TIMOTHY P | — |
| 17638869 | REBAMIPIDE FOR USE IN PROPHYLAXIS AND TREATMENT OF CANCER | LADD, CAROLYN LOUISE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17638871 | REBAMIPIDE FOR USE IN PREVENTION AND TREATMENT OF CROHN'S DISEASE | KETCHAM, KAREN A | 50d overdue |
| 17638868 | REBAMIPIDE FOR USE IN PROPHYLAXIS AND TREATMENT OF CELIAC DISEASE | THOMAS, TIMOTHY P | — |
| 17638869 | REBAMIPIDE FOR USE IN PROPHYLAXIS AND TREATMENT OF CANCER | LADD, CAROLYN LOUISE | — |
| Art Unit | Apps |
|---|---|
| 1614 | 2 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17638868 | REBAMIPIDE FOR USE IN PROPHYLAXIS AND TREATMENT OF CELIAC DISEASE | THOMAS, TIMOTHY P | 1614 | §103 | Final Rejection | — | Pending | Feb 28, 2022 |
| 17638871 | REBAMIPIDE FOR USE IN PREVENTION AND TREATMENT OF CROHN'S DISEASE | KETCHAM, KAREN A | 1614 | §103 | Final Rejection | 50d overdue | Pending | Feb 28, 2022 |
| 17638869 | REBAMIPIDE FOR USE IN PROPHYLAXIS AND TREATMENT OF CANCER | LADD, CAROLYN LOUISE | 1622 | §102§103§112Other | Non-Final OA | — | Pending | Feb 28, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial